Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Plasma Exchange in Acute IPF Exacerbations
NCT01524068Phase 2Withdrawn
- Sponsor
- University of Pittsburgh
- Start
- Sep 2012
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in idiopathic pulmonary fibrosis (IPF), sponsored by University of Pittsburgh. Planned start Sep 2012; status: withdrawn.
02
Drugs
rituximab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01524068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01524068.